| Literature DB >> 29856703 |
Helena Žemličková1,2, Lucia Mališová1, Petra Španělová1, Vladislav Jakubů1, Jana Kozáková1, Martin Musílek1, Matej Medvecký3.
Abstract
Purpose. The aim of this study was to characterize serogroup 19 isolates resistant to macrolides and/or penicillin found among pneumococci recovered from cases of invasive and respiratory tract disease in the Czech Republic in 2014.Methods. Pneumococcal isolates of serotypes 19A (n=26) and 19F (n=10) that were non-susceptible to penicillin and/or macrolides and had been collected in 2014 were analysed using multi-locus sequence typing (MLST). Four isolates representing the major clones were subjected to whole-genome sequencing (WGS).Results. The penicillin-susceptible macrolide-resistant isolates of serotype 19A were mainly associated with sequence type (ST) 416 belonging to clonal complex (CC) 199, and the penicillin-resistant isolates were of serotype 19F belonging to ST1464 (CC 320). WGS revealed the presence of pilus 1, in association with pilus 2, in serotype19F isolates belonging to CC 320. Another adhesin, pneumococcal serine-rich protein (PsrP), was only present in serotype 19A isolates of ST416. Analysis of the penicillin-binding proteins (PBPs) of serotype 19F penicillin-resistant isolates (ST1464 and ST271) performed on PBP1a, 2b and 2x identified a large number of mutations in comparison to the reference strain, R6. Both isolates contained a unique PBP profile; however, they were highly similar to PBP sequences of the Taiwan19F-14 reference strain. The Pbp2b sequences of both 19F isolates showed the lowest similarity to those of the Taiwan19F-14 strain (91 % similarity), while they were also found to be distantly related to each other (94 % similarity).Conclusions. WGS revealed specific virulence factors in antibiotic-resistant pneumococcal clones that spread rapidly in the post-vaccine era in the Czech Republic.Entities:
Keywords: MLST; Streptoccoccus pneumoniae; WGS
Mesh:
Substances:
Year: 2018 PMID: 29856703 PMCID: PMC6152367 DOI: 10.1099/jmm.0.000765
Source DB: PubMed Journal: J Med Microbiol ISSN: 0022-2615 Impact factor: 2.472
Characteristics of serogroup 19 isolates (n=36) obtained in the Czech Republic in 2014
| Isolates | Serotype | Source | MIC (µg ml−1) | ATB resistance genes | CC | ST | Allelic profile | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age | PEN | CTX | TET | ERY | CLI | CHL | SXT | PMEN clone | |||||||||||||
| 24 679 | 19A | Blood | 70 | 0.008 | 0.016 | 16.0 | >4.0 | 4.0 | 2.0 | 0.25 | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | Netherland15B-37/ST199 | |
| 26 584 | 19A | Blood | 60 | 0.008 | 0.016 | 16.0 | >4.0 | >4.0 | 4.0 | 0.25 | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | ||
| 27 270 | 19A | CSF | 36 | 0.016 | 0.016 | 16.0 | >4.0 | >4.0 | 2.0 | 0.25 | 199 | 416† | 1 | 13 | 14 | 4 | 17 | 51 | 14 | ||
| 27 374 | 19A | Ear | 3 | 0.016 | 0.016 | >16.0 | >4.0 | 4.0 | 2.0 | 0.25 | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | ||
| 27 389 | 19A | Ear | 3 | 0.016 | 0.016 | 16.0 | >4.0 | >4.0 | 2.0 | 0.25 | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | ||
| 27 417 | 19A | Blood | 64 | 0.016 | 0.016 | 16.0 | >4.0 | 4.0 | 4.0 | 0.25 | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | ||
| 27 491 | 19A | Ear | 3 | <0.004 | 0.016 | <0.125 | >4.0 | >4.0 | 2.0 | 0.25 | 199 | 416† | 1 | 13 | 14 | 4 | 17 | 51 | 14 | ||
| 27 630 | 19A | Blood | 68 | 0.016 | 0.016 | 16.0 | >4.0 | >4.0 | 2.0 | 0.25 | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | ||
| 27 775 | 19A | Ear | Unknown | 0.008 | 0.016 | 16.0 | >4.0 | >4.0 | 2.0 | 0.25 | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | ||
| 27 776 | 19A | Ear | Unknown | 0.016 | 0.016 | 16.0 | >4.0 | >4.0 | 2.0 | 0.25 | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | ||
| 27 806 | 19A | Ear | 0 | 0.016 | 0.016 | 16.0 | >4.0 | >4.0 | 2.0 | 0.25 | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | ||
| 27 844 | 19A | Sputum | 62 | 0.016 | 0.016 | 16.0 | >4.0 | >4.0 | 2.0 | 0.25 | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | ||
| 27 854 | 19A | Ear | 3 | 0.016 | 0.03 | 16.0 | >4.0 | >4.0 | 2.0 | 0.25 | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | ||
| 27 897 | 19A | Nose | 6 | 0.016 | <0.004 | >16.0 | >4.0 | >4.0 | 2.0 | 0.5 | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | ||
| 28 206 | 19A | Blood | 73 | 0.008 | 0.03 | <0.125 | >4.0 | 2.0 | 2.0 | 0.5 | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | ||
| 28 240 | 19A | Ear | 0 | 0.008 | 0.03 | 16.0 | >4.0 | >4.0 | 2.0 | 0.5 | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | ||
| 24 417 | 19A | Blood | 48 | 0.125 | 0.06 | <0.125 | 0.06 | 0.06 | 2.0 | 0.25 | 199 | 1756 | 8 | 20 | 14 | 4 | 17 | 4 | 14 | ||
| 25 138 | 19A | Blood | 71 | 0.008 | 0.03 | >16.0 | >4.0 | >4.0 | 2.0 | 0.25 | 199 | 11 198 | 1 | 13 | 14 | 4 | 199 | 51 | 14 | ||
| 25 137 | 19F | Blood | 57 | 8.0 | 4.0 | 16.0 | >4.0 | >4.0 | 0.5 | >4.0 | 320 | 271† | 4 | 16 | 19 | 15 | 6 | 20 | 26 | Taiwan19F-14/ST236 | |
| 27 722 | 19A | Sputum | 67 | 2.0 | 1.0 | 16.0 | >4.0 | >4.0 | 2.0 | >4.0 | 320 | 1464 | 4 | 16 | 19 | 15 | 6 | 20 | 106 | ||
| 24 238 | 19F | CSF | 73 | 4.0 | 2.0 | 8.0 | >4.0 | >4.0 | 2.0 | >4.0 | 320 | 1464† | 4 | 16 | 19 | 15 | 6 | 20 | 106 | ||
| 24 633 | 19F | Sputum | 56 | 4.0 | 2.0 | 16.0 | >4.0 | >4.0 | 4.0 | >4.0 | 320 | 1464 | 4 | 16 | 19 | 15 | 6 | 20 | 106 | ||
| 24 870 | 19F | Sputum | 65 | 4.0 | 2.0 | 16.0 | >4.0 | >4.0 | 2.0 | >4.0 | 320 | 1464 | 4 | 16 | 19 | 15 | 6 | 20 | 106 | ||
| 24 993 | 19F | Sputum | 62 | 4.0 | 2.0 | 16.0 | >4.0 | >4.0 | 4.0 | >4.0 | 320 | 1464 | 4 | 16 | 19 | 15 | 6 | 20 | 106 | ||
| 27 721 | 19F | Sputum | 60 | 2.0 | 1.0 | 16.0 | >4.0 | >4.0 | 2.0 | >4.0 | 320 | 1464 | 4 | 16 | 19 | 15 | 6 | 20 | 106 | ||
| 27 723 | 19F | Sputum | 61 | 2.0 | 1.0 | 16.0 | >4.0 | >4.0 | 2.0 | >4.0 | 320 | 1464 | 4 | 16 | 19 | 15 | 6 | 20 | 106 | ||
| 27 992 | 19F | Blood | 67 | 4.0 | 2.0 | 16.0 | >4.0 | >4.0 | 2.0 | >4.0 | 320 | 1464 | 4 | 16 | 19 | 15 | 6 | 20 | 106 | ||
| 28 205 | 19F | Sputum | 73 | 4.0 | 2.0 | 16.0 | >4.0 | >4.0 | 2.0 | >4.0 | 320 | 1464 | 4 | 16 | 19 | 15 | 6 | 20 | 106 | ||
| 24 493 | 19A | Blood | 21 | 0.25 | 0.25 | 16.0 | >4.0 | >4.0 | 2.0 | 0.125 | 230 | 230 | 12 | 19 | 2 | 17 | 6 | 22 | 14 | Denmark14-32/ST230 | |
| 28 258 | 19A | Sputum | 69 | 0.5 | 0.125 | 16.0 | >4.0 | 0.5 | 2.0 | 0.125 | 230 | 230 | 12 | 19 | 2 | 17 | 6 | 22 | 14 | ||
| 27 314 | 19A | Blood | 61 | 2.0 | 1.0 | 16.0 | >4.0 | 0.125 | 2.0 | 1.0 | 230 | 276 | 2 | 19 | 2 | 17 | 6 | 22 | 14 | ||
| 25 833 | 19A | Blood | 60 | 0.5 | 0.25 | >16.0 | 0.06 | 0.125 | 2.0 | >4.0 | 230 | 2013 | 12 | 19 | 36 | 17 | 6 | 20 | 14 | ||
| 27 227 | 19A | Ear | 3 | 0.016 | 0.016 | >16.0 | >4.0 | >4.0 | 2.0 | 0.25 | 193 | 3863 | 8 | 10 | 211 | 16 | 1 | 26 | 1 | Greece21-30/ST193 | |
| 29 469 | 19A | Blood | 4 | 0.016 | 0.016 | 16.0 | >4.0 | >4.0 | 2.0 | 0.25 | 193 | 3863 | 8 | 10 | 211 | 16 | 1 | 26 | 1 | ||
| 28 087 | 19F | Blood | 79 | 0.125 | 0.06 | 16.0 | 4.0 | >4.0 | 4.0 | 0.5 | 177 | 179 | 7 | 14 | 40 | 12 | 1 | 1 | 14 | Portugal19F-21/ST177 | |
| 27 102 | 19A | Ear | 5 | <0.004 | 0.008 | >16.0 | >4.0 | 0.125 | 16.0 | 4.0 | 66 | 11 197 | 1 | 5 | 41 | 5 | 10 | 616 | 8 | ||
PEN, penicilin; CTX, cefotaxime; TET, tetracycline; ERY, erytromycin; CLI, clindamycin; CHL, chloramphenicol; SXT, trimethoprim/sulfamethoxazole; CC, clonal complex; ST, sequence type; PMEN, Pneumococcal Molecular Epidemiology Network.
New sequence types are shown in bold.
*Isolates were found to be phenotypically susceptible due to the deletion of a 26-bp-long segment (from nucleotide position 16 298 to 16323) of the tetM gene.
†Isolates included in the whole-genome sequencing.
Fig. 1.Genetic relationship of PBP1a, PBP2b and PBP2x amino acid sequences. (a–c) Pair-wise alignments generated by BioNumerics 7.6. showing the relatedness of pbp1a (a), pbp2b (b) and pbp2x (c) nucleotide sequences among penicillin-susceptible R6, multidrug-resistant 19F A026, Taiwan19F-14, Hungary19A-6 and 19A/19F isolates. (d) Amino acid substitution sites of PBP2b. The sequences were aligned according to the corresponding amino acid sequences of R6. PEN, penicillin; CTX, cefotaxime; S, susceptible; R, resistant.